Figure 4
From: HSV1 microRNAs in glioblastoma development: an in silico study
Characterizing hsv1-miR-H1-5p targets. (A) MELK expression, (B) FZD2 expression, (C) IL1RN expression, (D) NOVA1 expression, (E) PTPRZ1 expression, (F) TMEM97 expression, (G) PDGFC expression, (H) MYH10 expression, (I) the prognostic values of MELK, FZD2, IL1RN, NOVA1, PTPRZ1, TMEM97, and PDGFC in GBM patients. (J) Drug sensitivity analysis of MELK, FZD2, IL1RN, NOVA1, PTPRZ1, TMEM97, and PDGFC based on GDSC. (K) Drug sensitivity analysis of MELK, FZD2, IL1RN, NOVA1, PTPRZ1, TMEM97, and PDGFC based on CTRP. (L–O) MELK, PTPRZ1, NOVA1, and TMEM97 expression in temozolomide-resistant GBM cell lines and normal astrocyte cells. (P) PDGFC staining in GBM cells, (Q) PTPRZ1 staining in GBM cells, (R) NOVA1 staining in GBM cells. (S) Immune cell infiltration and hsv1-miR-H1-5p targets in GBM tissues. (T) Enrichment analyses of hsv1-miR-H1-5p targets.
